Qijun Yang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Qijun Yang has a total of 75 co-authors. Here are the top co-authors by number of shared publications:
- Carlos Roberto Simons Linares
Department of Gastroenterology, Loyola University Medical Center, Maywood, USA
2 shared publications - John McMichael
Digestive Disease Institute
2 shared publications - Leandro Sierra
Department of Medicine, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
2 shared publications - Omar T. Sims
Department of Gastroenterology, Hepatology and Nutrition, Cleveland Clinic Foundation, Cleveland, OH, USA
2 shared publications Renan Prado
Internal Medicine Residency Program, Cleveland Clinic Foundation, Cleveland, Ohio
2 shared publications- Abel Joseph
Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, CA, USA
1 shared publication
Latest Publications
- 29 October 2026
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
Metachronous Advanced Neoplasia in Early Onset Colorectal Cancer
BACKGROUND: The risk of post-operative metachronous advanced colorectal neoplasia (MAN) among patients with sporadic average-onset colorectal cancer (AOCRC: ≥50 years) is well studied, whereas comparative risk in early-onset colorectal cancer (EOCRC: <50 years) remains unclear. Post-operative CRC surveillance guidelines are primarily based on studies in AOCRC cohorts and may not represent optimal post-operative surveillance intervals in EOCRC. AIMS: To compare the incidence of MAN between patients with sporadic AOCRC and EOCRC and to identify clinical risk factors associated with MAN. METHODS: In this retrospective cohort study, patients with EOCRC and AOCRC who underwent ≥1 postoperative surveillance lower endoscopies between 2011-2021 were included. Patients with inflammatory bowel disease, total proctocolectomy, and hereditary CRC syndromes were excluded. The most advanced metachronous lesion detected during postoperative surveillance was categorized as normal, nonadvanced neoplasia (NAN), or MAN. RESULTS: 230 EOCRC patients and 504 AOCRC patients (median age 44 and 66, respectively) were included. Overall rates of MAN were similar between EOCRC and AOCRC groups (13% vs. 16.1%, p = 0.342), however, AOCRC patients had a significantly lower MAN-free survival than EOCRC patients. In EOCRC patients, metachronous NAN, as the most advanced lesion detected during follow-up, was less frequent (17% vs. 26%, p = 0.009), the interval between CRC surgery and first surveillance endoscopy was shorter, and the follow up time was longer than in AOCRC patients. Older age, smoking exposure, and a distally located (descending and/or sigmoid colon) index cancer were independently associated with the development of MAN. CONCLUSION: Our study did not identify a sufficiently increased burden of MAN in EOCRC to support an age-specific surveillance strategy. Smoking is associated with MAN and should be avoided in CRC patients.
- 29 October 2026
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
Metachronous Advanced Neoplasia in Early Onset Colorectal Cancer
BACKGROUND: The risk of post-operative metachronous advanced colorectal neoplasia (MAN) among patients with sporadic average-onset colorectal cancer (AOCRC: ≥50 years) is well studied, whereas comparative risk in early-onset colorectal cancer (EOCRC: <50 years) remains unclear. Post-operative CRC surveillance guidelines are primarily based on studies in AOCRC cohorts and may not represent optimal post-operative surveillance intervals in EOCRC. AIMS: To compare the incidence of MAN between patients with sporadic AOCRC and EOCRC and to identify clinical risk factors associated with MAN. METHODS: In this retrospective cohort study, patients with EOCRC and AOCRC who underwent ≥1 postoperative surveillance lower endoscopies between 2011-2021 were included. Patients with inflammatory bowel disease, total proctocolectomy, and hereditary CRC syndromes were excluded. The most advanced metachronous lesion detected during postoperative surveillance was categorized as normal, nonadvanced neoplasia (NAN), or MAN. RESULTS: 230 EOCRC patients and 504 AOCRC patients (median age 44 and 66, respectively) were included. Overall rates of MAN were similar between EOCRC and AOCRC groups (13% vs. 16.1%, p = 0.342), however, AOCRC patients had a significantly lower MAN-free survival than EOCRC patients. In EOCRC patients, metachronous NAN, as the most advanced lesion detected during follow-up, was less frequent (17% vs. 26%, p = 0.009), the interval between CRC surgery and first surveillance endoscopy was shorter, and the follow up time was longer than in AOCRC patients. Older age, smoking exposure, and a distally located (descending and/or sigmoid colon) index cancer were independently associated with the development of MAN. CONCLUSION: Our study did not identify a sufficiently increased burden of MAN in EOCRC to support an age-specific surveillance strategy. Smoking is associated with MAN and should be avoided in CRC patients.
- Open Access
- 20 April 2026
- Published by Elsevier in Surgery for Obesity and Related Diseases
- Vol. 22  (8) , 885-890
Outcomes of conversion from sleeve gastrectomy to Roux-en-Y gastric bypass for the treatment of gastroesophageal reflux disease
- 20 April 2026
- Published by Elsevier in Surgery for Obesity and Related Diseases
- Vol. 22  (8) , 885-890
Open AccessOutcomes of conversion from sleeve gastrectomy to Roux-en-Y gastric bypass for the treatment of gastroesophageal reflux disease
- Open Access
- 28 August 2025
- Published by Wolters Kluwer Health in Clinical and Translational Gastroenterology
- Vol. 16  (11) , e00913
Adenoma and Sessile Serrated Polyp Detection Rates in Adults Using Glucagon-Like Peptide-1 Receptor Agonists
INTRODUCTION: Glucagon-like peptide-1 receptor agonists (GLP-1RA) are increasingly used for managing diabetes and obesity. Although they improve glycemic control, they also delay gastrointestinal motility, potentially leading to inadequate bowel preparation for colonoscopy, which can increase the risk of missed lesions. This study aimed to evaluate the impact of GLP-1RA use on the quality of bowel preparation and on adenomas and sessile serrated polyp (SSP) detection. METHODS: We conducted a retrospective cohort study of outpatient screening and surveillance colonoscopies at a tertiary academic medical center. Adults who used a GLP-1RA within 1 week of their colonoscopy formed the treatment group; patients not on GLP-1RA (nonusers) who never used GLP-1RA served as controls. Propensity score weighting was applied for age, sex, BMI, race, diabetes status, and relevant medications. The subgroup analysis was stratified based on diabetes status and GLP-1RA use. RESULTS: Among 49,987 patients (4,269 GLP-1RA users, 45,718 nonusers), GLP-1RA use was associated with increased odds of inadequate bowel preparation (odds ratio [OR] 1.23, 95% confidence interval [CI] 1.04–1.46). No significant difference in SSP and adenoma detection was observed. In subgroup analysis, GLP-1RA users with diabetes had the highest odds of inadequate preparation (OR 1.88, 95% CI 1.59–2.24) and the lowest odds of SSP detection (OR 0.71, 95% CI 0.57–0.89). DISCUSSION: GLP-1RA use, particularly among patients with diabetes, is associated with higher odds of inadequate bowel preparation and lower SSP detection, whereas adenoma detection was unaffected. Tailored bowel-prep protocols for GLP-1RA users with diabetes should be evaluated prospectively.
- 28 August 2025
- Published by Wolters Kluwer Health in Clinical and Translational Gastroenterology
- Vol. 16  (11) , e00913
Open AccessAdenoma and Sessile Serrated Polyp Detection Rates in Adults Using Glucagon-Like Peptide-1 Receptor Agonists
INTRODUCTION: Glucagon-like peptide-1 receptor agonists (GLP-1RA) are increasingly used for managing diabetes and obesity. Although they improve glycemic control, they also delay gastrointestinal motility, potentially leading to inadequate bowel preparation for colonoscopy, which can increase the risk of missed lesions. This study aimed to evaluate the impact of GLP-1RA use on the quality of bowel preparation and on adenomas and sessile serrated polyp (SSP) detection. METHODS: We conducted a retrospective cohort study of outpatient screening and surveillance colonoscopies at a tertiary academic medical center. Adults who used a GLP-1RA within 1 week of their colonoscopy formed the treatment group; patients not on GLP-1RA (nonusers) who never used GLP-1RA served as controls. Propensity score weighting was applied for age, sex, BMI, race, diabetes status, and relevant medications. The subgroup analysis was stratified based on diabetes status and GLP-1RA use. RESULTS: Among 49,987 patients (4,269 GLP-1RA users, 45,718 nonusers), GLP-1RA use was associated with increased odds of inadequate bowel preparation (odds ratio [OR] 1.23, 95% confidence interval [CI] 1.04–1.46). No significant difference in SSP and adenoma detection was observed. In subgroup analysis, GLP-1RA users with diabetes had the highest odds of inadequate preparation (OR 1.88, 95% CI 1.59–2.24) and the lowest odds of SSP detection (OR 0.71, 95% CI 0.57–0.89). DISCUSSION: GLP-1RA use, particularly among patients with diabetes, is associated with higher odds of inadequate bowel preparation and lower SSP detection, whereas adenoma detection was unaffected. Tailored bowel-prep protocols for GLP-1RA users with diabetes should be evaluated prospectively.
- 22 August 2025
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 121  (6) , 1501-1508
Fatty Pancreas Disease and the Risk of Future Diseases of the Exocrine Pancreas: A US Matched Cohort Study
INTRODUCTION: Fatty pancreas disease (FPD), marked by excess fat within the pancreas, is often incidentally detected on imaging. Despite recognized metabolic links, its clinical significance remains unclear. More granular data from large, well-characterized US cohorts are needed to clarify its relevance. This study quantified intrapancreatic fat deposition and assess its natural history and related outcomes. METHODS: Adults 18 years and older with radiologically confirmed FPD between 2004 and 2024 were identified from institutional databases. Controls without FPD were matched 1:2 by age, sex, body mass index, and smoking status. Patients with excessive alcohol intake, previous pancreatitis, pancreatic cancer, surgery, cystic fibrosis, or prolonged steroid/antiviral use were excluded. Fat content in the pancreas and liver, as well as subcutaneous and visceral fat areas, were measured using iNtuition software on noncontrast computed tomography scans. RESULTS: We included 82 FPD patients and 164 matched controls (median age 65 years; 55% women; median body mass index 32). Subcutaneous and hepatic fat were similar between groups, but intrapancreatic fat deposition was markedly higher in FPD patients (26.8% vs 4.9%, P < 0.001). Over a mean 4-year follow-up, FPD patients had significantly higher rates of acute pancreatitis (12% vs 1.2%, P < 0.001), chronic pancreatitis (6.1% vs 0.6%, P = 0.017), pancreatic cysts (34.1% vs 4.9%, P < 0.001), and pancreatic cancer (1.6% vs 0%, P = 0.012). Extrapancreatic cancer incidence did not differ. DISCUSSION: FPD is associated with an increased risk of pancreatic cancer, acute pancreatitis, chronic pancreatitis, and incidental pancreatic cysts, independent of obesity or hepatic steatosis, suggesting a potentially causative role of FPD in the pathogenesis of exocrine pancreatic diseases.
- 22 August 2025
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 121  (6) , 1501-1508
Fatty Pancreas Disease and the Risk of Future Diseases of the Exocrine Pancreas: A US Matched Cohort Study
INTRODUCTION: Fatty pancreas disease (FPD), marked by excess fat within the pancreas, is often incidentally detected on imaging. Despite recognized metabolic links, its clinical significance remains unclear. More granular data from large, well-characterized US cohorts are needed to clarify its relevance. This study quantified intrapancreatic fat deposition and assess its natural history and related outcomes. METHODS: Adults 18 years and older with radiologically confirmed FPD between 2004 and 2024 were identified from institutional databases. Controls without FPD were matched 1:2 by age, sex, body mass index, and smoking status. Patients with excessive alcohol intake, previous pancreatitis, pancreatic cancer, surgery, cystic fibrosis, or prolonged steroid/antiviral use were excluded. Fat content in the pancreas and liver, as well as subcutaneous and visceral fat areas, were measured using iNtuition software on noncontrast computed tomography scans. RESULTS: We included 82 FPD patients and 164 matched controls (median age 65 years; 55% women; median body mass index 32). Subcutaneous and hepatic fat were similar between groups, but intrapancreatic fat deposition was markedly higher in FPD patients (26.8% vs 4.9%, P < 0.001). Over a mean 4-year follow-up, FPD patients had significantly higher rates of acute pancreatitis (12% vs 1.2%, P < 0.001), chronic pancreatitis (6.1% vs 0.6%, P = 0.017), pancreatic cysts (34.1% vs 4.9%, P < 0.001), and pancreatic cancer (1.6% vs 0%, P = 0.012). Extrapancreatic cancer incidence did not differ. DISCUSSION: FPD is associated with an increased risk of pancreatic cancer, acute pancreatitis, chronic pancreatitis, and incidental pancreatic cysts, independent of obesity or hepatic steatosis, suggesting a potentially causative role of FPD in the pathogenesis of exocrine pancreatic diseases.
- Open Access
- 5 June 2025
- Published by Springer Nature in Obesity Surgery
- Vol. 35  (7) , 2736-2744
Preoperative Upper Endoscopy and Surgical Specimen Findings in Bariatric Surgery Patients
Background: The role of routine esophagogastroduodenoscopy (EGD) before metabolic bariatric surgery (MBS) remains unclear. We examined which patients were more likely to undergo preoperative EGD with biopsies, assessed the prevalence of clinically significant gastric pathologies on surgical specimens that may have been missed preoperatively, and analyzed patient factors associated with those findings. Methods: Patients ≥ 18 years old with Roux-en-Y gastric bypass (RYGB) or sleeve gastrectomy (SG) between 2018 and 2022 were included. Demographic, clinical, endoscopic, and pathology (from EGD and surgical specimens) characteristics were collected. Descriptive statistics were used. Uni- and multivariable Cox regression analyses assessed factors associated with clinically significant endoscopic and pathology findings. Results: Of 3718 patients (38.8% RYGB, 61.2% SG), 80% were female, 69.9% White, and 12.6% Hispanic. Median age at surgery was 45.7 years; median body mass index was 44.5 kg/m2. Preoperative EGD was performed in 36.9% of patients. Surgical specimens were available for 2349 patients (2273 SG and 76 RYGB), among whom 135 had clinically significant pathology. 63.7% of these patients had no preoperative EGD, 15.6% had preoperative EGD without biopsies, and 20.7% preoperative EGD with biopsies. Older age and non-White, non-Black race were associated with clinically significant findings on EGD or pathology. Conclusions: Several clinically relevant gastric pathologies could have been detected preoperatively via EGD with biopsies, yet about two-thirds did not undergo this evaluation. Older age and non-White, non-Black race were associated with these findings. Further research is needed to assess predictive factors of significant findings and cost-effectiveness of routine versus selective pre-operative EGD.
- 5 June 2025
- Published by Springer Nature in Obesity Surgery
- Vol. 35  (7) , 2736-2744
Open AccessPreoperative Upper Endoscopy and Surgical Specimen Findings in Bariatric Surgery Patients
Background: The role of routine esophagogastroduodenoscopy (EGD) before metabolic bariatric surgery (MBS) remains unclear. We examined which patients were more likely to undergo preoperative EGD with biopsies, assessed the prevalence of clinically significant gastric pathologies on surgical specimens that may have been missed preoperatively, and analyzed patient factors associated with those findings. Methods: Patients ≥ 18 years old with Roux-en-Y gastric bypass (RYGB) or sleeve gastrectomy (SG) between 2018 and 2022 were included. Demographic, clinical, endoscopic, and pathology (from EGD and surgical specimens) characteristics were collected. Descriptive statistics were used. Uni- and multivariable Cox regression analyses assessed factors associated with clinically significant endoscopic and pathology findings. Results: Of 3718 patients (38.8% RYGB, 61.2% SG), 80% were female, 69.9% White, and 12.6% Hispanic. Median age at surgery was 45.7 years; median body mass index was 44.5 kg/m2. Preoperative EGD was performed in 36.9% of patients. Surgical specimens were available for 2349 patients (2273 SG and 76 RYGB), among whom 135 had clinically significant pathology. 63.7% of these patients had no preoperative EGD, 15.6% had preoperative EGD without biopsies, and 20.7% preoperative EGD with biopsies. Older age and non-White, non-Black race were associated with clinically significant findings on EGD or pathology. Conclusions: Several clinically relevant gastric pathologies could have been detected preoperatively via EGD with biopsies, yet about two-thirds did not undergo this evaluation. Older age and non-White, non-Black race were associated with these findings. Further research is needed to assess predictive factors of significant findings and cost-effectiveness of routine versus selective pre-operative EGD.
- Open Access
- 1 February 2025
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 9  (2)
The impact of integrated care on clinical outcomes in patients with alcohol-associated liver disease: Early outcomes from a multidisciplinary clinic
Background: We analyzed early outcomes regarding the impact of our integrated alcohol-associated liver disease (ALD) clinic on patients with ALD and alcohol use. Methods: We conducted a retrospective study of patients with ALD who were evaluated in our integrated clinic from May 1, 2022, to December 31, 2023. Primary outcomes included differences in baseline clinical/demographic data between patients who accepted versus declined an appointment and changes in the severity of ALD, alcohol consumption, functional status, hospital utilization, and remission in alcohol use disorder for evaluated patients. Results: Patients who declined appointments (n=66) had higher median no-show rates (15.0 [8.0,30.0] vs. 8.5 [3.25,15.0], p p =0.033), and proportions of cirrhosis (78.8% vs. 59.8%, p =0.017) versus evaluated patients. Comparison of baseline to first follow-up visit for evaluated patients (n=102) demonstrated significant reductions in median AST (59.5 [41.75, 89] vs. 44.5 [33.5, 56.25], p p =0.017), total bilirubin (1.6 [0.7,3.3] vs. 1 [0.5,1.9], p= 0.001), phosphatidylethanol (263 [35, 784] vs. 0 [0, 163], p p p p p p =0.002) and 0.71 hospital admissions/month ( p =0.025). However, after considering the false discovery rate, the reduction in hospitalization admissions/month was not statistically significant (False Discovery Rate adjusted p =0.056). Conclusions: Our integrated approach led to reductions in liver injury, degree of liver decompensation, alcohol use, and ED utilization, and remission in AUD in a population of both non-transplant ALD and post-transplant patients.
- 1 February 2025
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 9  (2)
Open AccessThe impact of integrated care on clinical outcomes in patients with alcohol-associated liver disease: Early outcomes from a multidisciplinary clinic
Background: We analyzed early outcomes regarding the impact of our integrated alcohol-associated liver disease (ALD) clinic on patients with ALD and alcohol use. Methods: We conducted a retrospective study of patients with ALD who were evaluated in our integrated clinic from May 1, 2022, to December 31, 2023. Primary outcomes included differences in baseline clinical/demographic data between patients who accepted versus declined an appointment and changes in the severity of ALD, alcohol consumption, functional status, hospital utilization, and remission in alcohol use disorder for evaluated patients. Results: Patients who declined appointments (n=66) had higher median no-show rates (15.0 [8.0,30.0] vs. 8.5 [3.25,15.0], p p =0.033), and proportions of cirrhosis (78.8% vs. 59.8%, p =0.017) versus evaluated patients. Comparison of baseline to first follow-up visit for evaluated patients (n=102) demonstrated significant reductions in median AST (59.5 [41.75, 89] vs. 44.5 [33.5, 56.25], p p =0.017), total bilirubin (1.6 [0.7,3.3] vs. 1 [0.5,1.9], p= 0.001), phosphatidylethanol (263 [35, 784] vs. 0 [0, 163], p p p p p p =0.002) and 0.71 hospital admissions/month ( p =0.025). However, after considering the false discovery rate, the reduction in hospitalization admissions/month was not statistically significant (False Discovery Rate adjusted p =0.056). Conclusions: Our integrated approach led to reductions in liver injury, degree of liver decompensation, alcohol use, and ED utilization, and remission in AUD in a population of both non-transplant ALD and post-transplant patients.
- 15 July 2024
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 119  (12) , 2493-2500
Histologic Activity From Neoterminal Ileal Biopsies in Patients With Crohn's Disease in Endoscopic Remission is Associated With Postoperative Recurrence
INTRODUCTION: Following ileocolic resection (ICR), the clinical importance and prognostic implications of histologic activity on biopsies in Crohn's disease (CD) patients with endoscopic remission are not well defined. The aim of this study was to determine if histologic activity in patients with endoscopic remission is associated with future risk of endoscopic and/or radiologic postoperative recurrence (POR). METHODS: In this multicenter retrospective cohort study, adult patients with CD who underwent ICR between 2009 and 2020 with endoscopic biopsies of ileal mucosa from Rutgeerts i0 on index colonoscopy were included. The composite rate of endoscopic (Rutgeerts score ≥i2b) and radiologic (active inflammation on imaging) recurrence was compared in patients with and without histologic activity using a Kaplan-Meier survival analysis. A multivariable Cox proportional hazard regression model including clinically relevant risk factors of POR, postoperative biologic prophylaxis, and histology activity was designed. RESULTS: A total of 113 patients with i0 disease on index colonoscopy after ICR were included. Of these, 42% had histologic activity. Time to POR was significantly earlier in the histologically active versus normal group (P = 0.04). After adjusting for clinical risk factors of POR, histologic activity (HR 2.37, 95% CI 1.17–4.79; P = 0.02) and active smoking (HR 2.54, 95% CI 1.02–6.33; P = 0.05) were independently associated with subsequent composite POR risk. DISCUSSION: In patients with postoperative CD, histologic activity despite complete endoscopic remission is associated with composite, endoscopic, and radiographic recurrence. Further understanding of the role of histologic activity in patients with Rutgeerts i0 disease may provide a novel target to reduce disease recurrence in this population.
- 15 July 2024
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 119  (12) , 2493-2500
Histologic Activity From Neoterminal Ileal Biopsies in Patients With Crohn's Disease in Endoscopic Remission is Associated With Postoperative Recurrence
INTRODUCTION: Following ileocolic resection (ICR), the clinical importance and prognostic implications of histologic activity on biopsies in Crohn's disease (CD) patients with endoscopic remission are not well defined. The aim of this study was to determine if histologic activity in patients with endoscopic remission is associated with future risk of endoscopic and/or radiologic postoperative recurrence (POR). METHODS: In this multicenter retrospective cohort study, adult patients with CD who underwent ICR between 2009 and 2020 with endoscopic biopsies of ileal mucosa from Rutgeerts i0 on index colonoscopy were included. The composite rate of endoscopic (Rutgeerts score ≥i2b) and radiologic (active inflammation on imaging) recurrence was compared in patients with and without histologic activity using a Kaplan-Meier survival analysis. A multivariable Cox proportional hazard regression model including clinically relevant risk factors of POR, postoperative biologic prophylaxis, and histology activity was designed. RESULTS: A total of 113 patients with i0 disease on index colonoscopy after ICR were included. Of these, 42% had histologic activity. Time to POR was significantly earlier in the histologically active versus normal group (P = 0.04). After adjusting for clinical risk factors of POR, histologic activity (HR 2.37, 95% CI 1.17–4.79; P = 0.02) and active smoking (HR 2.54, 95% CI 1.02–6.33; P = 0.05) were independently associated with subsequent composite POR risk. DISCUSSION: In patients with postoperative CD, histologic activity despite complete endoscopic remission is associated with composite, endoscopic, and radiographic recurrence. Further understanding of the role of histologic activity in patients with Rutgeerts i0 disease may provide a novel target to reduce disease recurrence in this population.